Compound: Lercanidipine
SMILES: O=[N+]([O-])c1cc(ccc1)C2C(=C(NC(=C2C(=O)OC)C)C)C(=O)OC(CN(CCC(c3ccccc3)c4ccccc4)C)(C)C
InChIKey: ZDXUKAKRHYTAKV-UHFFFAOYSA-N
Synonyms: Lercanidipine, 100427-26-7, Lercanil, Lercanidipino, V7XTJ4R0BH, 3-(1-((3,3-diphenylpropyl)(methyl)amino)-2-methylpropan-2-yl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate, 3-{1-[(3,3-diphenylpropyl)(methyl)amino]-2-methylpropan-2-yl} 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate, DTXSID2048327, Lerdip, REC-15-2375, lercanidipinum, RefChem:152876, methyl-1,1-dimethyl-2-(N-(3,3-diphenylpropyl)-N-methylamino)ethyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate, DTXCID7028302, C08CA13, Lercanidipine [INN], 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 3-[2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl] 5-methyl ester, Lercanidipine (INN), 5-O-[1-[3,3-diphenylpropyl(methyl)amino]-2-methylpropan-2-yl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate, 1-[(3,3-diphenylpropyl)(methyl)amino]-2-methylpropan-2-yl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate, C36H41N3O6, Lercanil (TN), NCGC00167492-01, UNII-V7XTJ4R0BH, Lercanidipine [INN:BAN], Lercanidipine?, MFCD00867978, LERCANIDIPINE [MI], SCHEMBL25268, LERCANIDIPINE [WHO-DD], CHEMBL250270, orb1305366, SCHEMBL6846222, SCHEMBL29541187, CHEBI:135930, ZDXUKAKRHYTAKV-UHFFFAOYSA-N, BDBM642527, GLXC-23060, HMS3604G05, HMS5085J13, HY-B0612, BBL029074, EBC-27382, s5861, STK639861, AKOS005571238, DB00528, SDCCGSBI-0633690.P001, US20230414632, Compound I-c, NCGC00167492-02, NCGC00167492-11, (+-)-2-((3,3-Diphenylpropyl)methylamino)-1,1-dimethylethyl methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate, AC-15409, AS-75252, O5-[2-[3,3-diphenylpropyl(methyl)amino]-1,1-dimethyl-ethyl] O3-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate, NS00002039, C13971, D08111, SBI-0633690.0001, EN300-19767833, Q410492, SR-01000884000, SR-01000884000-1, BRD-A18992208-003-02-7, 2-((3,3-DIPHENYLPROPYL)METHYLAMINO)-1,1-DIMETHYLETHYL METHYL (4RS)-2,6-DIMETHYL-4-(3-NITROPHENYL)-1,4-DIHYDROPYRIDINE-3,5-DICARBOXYLATE, 3,5-PYRIDINEDICARBOXYLIC ACID, 1,4-DIHYDRO-2,6-DIMETHYL-4-(3-NITROPHENYL)-, 2-((3,3-DIPHENYLPROPYL)METHYLAMINO)-1,1-DIMETHYLETHYL METHYL ESTER, 3,5-Pyridinedicarboxylic acid, 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-(3,3-diphenylpropyl)methylamino)-1,1-dimethylethyl methyl ester
Theoretical properties:
molecular_formula: C36H41N3O6
molecular_weight: 611.7 g/mol
exact_mass: 611.29953604 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 8
rotatable_bond_count: 13
heavy_atom_count: 45
topological_polar_surface_area: 114 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
solubility: 1.56e-04 g/L
Descriptions:
pubchem: Lercanidipine is a diarylmethane.
chembl: LERCANIDIPINE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 3.0.
wikipedia: Lercanidipine (INN) is an antihypertensive (blood pressure lowering) drug. It belongs to the dihydropyridine class of calcium channel blockers, which work by relaxing and opening the blood vessels allowing the blood to circulate more freely around the body. This lowers the blood pressure and allows the heart to work more efficiently.
This drug (trade name Zanidip, among others) acts more slowly than older dihydropyridines. It probably has fewer adverse effects, but a comparatively high potential for drug interactions.
It was patented in 1984 and first approved for medical use in 1997. The FDA refused to approve the drug, and lercanidipine is not marketed in the United States.